ClinicalTrials.gg
RecruitingNCT02507141Updated Nov 13, 2026

Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology

An observational study in Head and Neck Cancer and Squamous Cell Carcinoma (SCC) of the Oral Cavity, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started Jul 2015; still recruiting 11 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
140
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center — 6 open to participants now, 11 under way, none of them phase 3. Head and Neck Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
8th of 14
140 · median 152
Started
2015
with 2 others
Observational
14 of 52
4 open now
Primary completion
2027-07
later than 5 of 10 live
Registered
36th of 52
by date

Among the 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 8th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2015, is one of 14 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 36th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

6 of the 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Head and Neck Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to get images (pictures) of oral lesions, which occur inside the mouth, before the patient's surgery using a special camera. These pictures will be used in our research to evaluate a new technology that uses a laser and takes pictures of the microscopic structure of tissue. The technology is called "reflectance confocal microscopy." We would like to compare what the camera sees to biopsies (pathology) of the same area. We will evaluate the pictures obtained from the patient to determine whether this technology may be useful in the future. We hope this technology can be used as a tool for early diagnosis of oral cancers and for guiding surgery.

03

Conditions studied

  • Head and Neck Cancer
  • Squamous Cell Carcinoma (SCC) of the Oral Cavity

Keywords

  • Reflectance Confocal Microscopy
  • 15-128
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Potential research subjects in the Head and Neck Service will be identified by a member of the patient's treatment team, the protocol investigator, or a member of the research team at Memorial Sloan Kettering Cancer Center (MSK).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with -proven oral SCC who are scheduled to undergo surgery in the MSK Head and Neck Service.
  • Ability to sign .
  • Age ≥ 18 years.

Exclusion criteria

Exclusion Criteria:

  • Cancer located on a site that may not be convenient or accessible for imaging with the current version of the RCM device (gingivobuccal region, back of the oral cavity, back of the tongue, floor of the mouth, deep under the tongue, etc.).
  • Inability to give .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
140 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • SCC of the oral cavity scheduled for surgery

    The patients will be imaged for testing the feasibility of intra-oral imaging. Images will be compared to and evaluated against the corresponding pathology that is routinely prepared during surgery.

    Device: Reflectance Confocal Microscopy

Interventions

  • DeviceReflectance Confocal Microscopy

    Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.

06

What researchers measure

Primary outcomes

  1. Reflectance Confocal Microscopy (RCM) images

    Each set of images and the corresponding pathology will be evaluated by the study pathologist for the presence or absence of oral SCC. All images will be evaluated as a group. First, the pathologist will review the RCM images for each imaging site and will determine the presence/absence of tumor. Next, the pathologist will review the corresponding histopathologic material for the presence/absence of tumor. If there is discordance in the evaluations, the pathologist will re-evaluate the RCM images with the corresponding pathology, in a side-by-side manner, to highlight any features that may assist in the RCM evaluation.

    Time frame: 1 year

07

Study locations

5 of 5 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (consent only)
    Basking Ridge, New Jersey, United States
    Recruiting
    • Snehal Patel, MD · Contact212-639-3412
  • Memorial Sloan Kettering Monmouth (consent only)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Snehal Patel, MD · Contact212-639-3412
  • Memorial Sloan Kettering West Harrison (consent only)
    Harrison, New York 10604, United States
    Recruiting
    • Snehal Patel, MD · Contact212-639-3412
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Snehal Patel, MD · Contact212-639-3412
    • Milind Rajadhyaksha, PhD · Contact646-888-6243
    • Snehal Patel, MD · Principal investigator
  • Memorial Sloan Kettering Nassau (consent only)
    Uniondale, New York 11553, United States
    Recruiting
    • Snehal Patel, MD · Contact212-639-3412
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2015 (actual). Primary completion is estimated for Jul 2027, 144 months after the start.

Of 216 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 144 months is above that.

Counting every sponsor, half of 238 studies reached it within 69 months; a quarter within 29 and three quarters within 144.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2015
First posted
Jul 23, 2015
StartActual
Jul 21, 2015
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02507141
Responsible party
Sponsor
First posted
Jul 23, 2015
Start date
Jul 21, 2015
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Snehal Patel, MD
Contact
212-639-3412
Milind Rajadhyaksha, PhD
Contact
646-888-6243
Snehal Patel, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion